Pharsight

Drug Patents Expiring in 2031

1. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(7 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(7 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

2. Accrufer patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 2023-07-26

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

ACCRUFER family patents

Family Patents

3. Acetadote patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof
Jul, 2031

(7 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

4. Airduo Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(7 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(7 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(7 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(7 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(7 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(7 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(7 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(7 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

5. Akeega patents expiration

AKEEGA's oppositions filed in EPO
AKEEGA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8071623 JANSSEN BIOTECH Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859562 JANSSEN BIOTECH Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

More Information on Dosage

AKEEGA family patents

Family Patents

6. Aklief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 4, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 2023-10-05

Market Authorisation Date: 04 October, 2019

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

AKLIEF family patents

Family Patents

7. Akynzeo patents expiration

AKYNZEO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Sep, 2031

(7 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...

Dosage: CAPSULE;ORAL

More Information on Dosage

AKYNZEO family patents

Family Patents

8. Alecensa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9126931 HOFFMANN-LA ROCHE Tetracyclic compound
May, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents

9. Alunbrig patents expiration

ALUNBRIG's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 22, 2027

Drugs and Companies using BRIGATINIB ingredient

Market Authorisation Date: 28 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ALUNBRIG family patents

Family Patents

10. Angeliq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT
Oct, 2031

(7 years from now)

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 28 September, 2005

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage

ANGELIQ family patents

Family Patents

11. Anoro Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

12. Apadaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461137 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Feb, 2031

(6 years from now)

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

APADAZ family patents

Family Patents

13. Apretude patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

APRETUDE family patents

Family Patents

14. Armonair Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(7 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(7 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(7 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(7 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(7 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(7 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(7 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(7 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

15. Arnuity Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Mar 1, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

16. Aubagio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

17. Austedo patents expiration

AUSTEDO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
M (M) Jun 24, 2024
Pediatric Exclusivity (PED) Dec 24, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

18. Austedo Xr patents expiration

AUSTEDO XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(7 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUSTEDO XR family patents

Family Patents

19. Avycaz patents expiration

AVYCAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
New Patient Population (NPP) Dec 20, 2025
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 2024-02-26

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

Family Patents

20. Balversa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 2023-04-13

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemot...

Dosage: TABLET;ORAL

How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage

BALVERSA family patents

Family Patents

21. Barhemsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(7 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(7 years from now)

US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 2024-02-27

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BARHEMSYS family patents

Family Patents

22. Baxdela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 19, 2022
Generating Antibiotic Incentives Now (GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 2026-06-19

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

BAXDELA family patents

Family Patents

23. Belrapzo patents expiration

BELRAPZO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE* (ODE*) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic ...

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage

BELRAPZO family patents

Family Patents

24. Bendeka patents expiration

BENDEKA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic ...

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage

BENDEKA family patents

Family Patents

25. Besivance patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8481526 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Jan, 2031

(6 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

BESIVANCE family patents

Family Patents

26. Bevespi Aerosphere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(7 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BEVESPI AEROSPHERE family patents

Family Patents

27. Bevyxxa patents expiration

BEVYXXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404724 PORTOLA PHARMS INC Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 2021-06-23

Market Authorisation Date: 23 June, 2017

Treatment: Inhibiting coagulation

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

Family Patents

28. Binosto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592195 ASCEND THERAPS US Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
Dec, 2031

(7 years from now)

Drugs and Companies using ALENDRONATE SODIUM ingredient

Market Authorisation Date: 12 March, 2012

Treatment: NA

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage

BINOSTO family patents

Family Patents

29. Braftovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 11, 2030
New Indication (I) Oct 11, 2026

Drugs and Companies using ENCORAFENIB ingredient

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma mediated by a b-raf protein kinase; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer ...

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

30. Brenzavvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10981942 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jun, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10533032 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 2027-01-20

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

BRENZAVVY family patents

Family Patents

31. Breo Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 13, 2026
New Strength (NS) May 13, 2026
Pediatric Exclusivity (PED) Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

32. Breztri Aerosphere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination (NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BREZTRI AEROSPHERE family patents

Family Patents

33. Bryhali patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11839656 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2018

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of BRYHALI before it's drug patent expiration?
More Information on Dosage

BRYHALI family patents

Family Patents

34. Bydureon Bcise patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033

(Pediatric)

ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

35. Byfavo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 6, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 2024-10-06

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BYFAVO family patents

Family Patents

36. Bylvay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11732006 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10487111 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US9694018 ALBIREO IBAT inhibitors for the treatment of liver disease
Nov, 2031

(7 years from now)

US10981952 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10011633 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

US10093697 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028
New Indication (I) Jun 13, 2026

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 12 months or older suffering from alagille syndrome (algs); Method of treating cholestatic pruritus in patients 12 months or older suffering from alagil...

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

BYLVAY family patents

Family Patents

37. Cabenuva Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv infection in adults

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

Family Patents

38. Cabometyx patents expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(7 years from now)

US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of advanced renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

39. Cerdelga patents expiration

CERDELGA's oppositions filed in EPO
CERDELGA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(6 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); Long-term treatment of adu...

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage

CERDELGA family patents

Family Patents

40. Cleviprex patents expiration

CLEVIPREX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(7 years from now)

US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(7 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(7 years from now)

Drugs and Companies using CLEVIDIPINE ingredient

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage

CLEVIPREX family patents

Family Patents

41. Combogesic Iv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446266 HIKMA Combination composition
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 17, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient

Market Authorisation Date: 17 October, 2023

Treatment: Method of treating mild to moderate pain in adults; Method of treating moderate to severe pain in adults as an adjunct to opioid analgesics

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

COMBOGESIC IV family patents

Family Patents

42. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033543 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2031

(6 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

43. Cosela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

US10927120 G1 THERAP CDK inhibitors
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 2025-02-12

Market Authorisation Date: 12 February, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

COSELA family patents

Family Patents

44. Daklinza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629171 BRISTOL-MYERS SQUIBB Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Jun, 2031

(7 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage

DAKLINZA family patents

Family Patents

45. Daurismo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DAURISMO family patents

Family Patents

46. Dayvigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2025
M (M) Apr 20, 2026

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 2024-04-07

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

DAYVIGO family patents

Family Patents

47. Delstrigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to...

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's drug patent expiration?
More Information on Dosage

DELSTRIGO family patents

Family Patents

48. Docetaxel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842770 SHILPA Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
Aug, 2031

(7 years from now)

Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 December, 2015

Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion

Dosage: INJECTABLE;INJECTION

More Information on Dosage

DOCETAXEL family patents

Family Patents

49. Dovato patents expiration

DOVATO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Aug 6, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents

50. Drospirenone patents expiration

DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11351122 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

US11478487 EXELTIS USA INC NA
Jun, 2031

(7 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

DROSPIRENONE family patents

Family Patents

51. Dsuvia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945592 ACELRX PHARMS Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
Jul, 2031

(7 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

DSUVIA family patents

Family Patents

52. Duobrii patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US11839656 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of DUOBRII before it's drug patent expiration?
More Information on Dosage

DUOBRII family patents

Family Patents

53. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

54. Duzallo patents expiration

DUZALLO's oppositions filed in EPO
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia
Aug, 2031

(7 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Dec, 2031

(7 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

Family Patents

55. Ecoza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071054 RESILIA PHARMS Econazole composition and methods of treatment therewith
Aug, 2031

(7 years from now)

Drugs and Companies using ECONAZOLE NITRATE ingredient

Market Authorisation Date: 24 October, 2013

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

ECOZA family patents

Family Patents

56. Edarbyclor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387249 AZURITY Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Jul, 2031

(7 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

57. Edluar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(7 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage

EDLUAR family patents

Family Patents

58. Eliquis patents expiration

ELIQUIS's oppositions filed in EPO
ELIQUIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations
Feb, 2031

(6 years from now)

Drugs and Companies using APIXABAN ingredient

Market Authorisation Date: 28 December, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage

ELIQUIS family patents

Family Patents

59. Enstilar patents expiration

ENSTILAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(7 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(7 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Jan 30, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 16 October, 2015

Treatment: Topical treatment of plaque psoriasis in patients 12 years and older; Plaque psoriasis

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of ENSTILAR before it's drug patent expiration?
More Information on Dosage

ENSTILAR family patents

Family Patents

60. Epclusa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
M (M) Apr 27, 2025
Pediatric Exclusivity (PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS;ORAL

More Information on Dosage

EPCLUSA family patents

Family Patents

61. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US10143972 KALEO INC Ultrafiltration membrane and a preparation method thereof
May, 2031

(7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

62. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(7 years from now)

US10143792 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
May, 2031

(7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

63. Fanapt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072742 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Jan, 2031

(6 years from now)

US9074256 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Feb, 2031

(6 years from now)

US9074254 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2031

(7 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Market Authorisation Date: 06 May, 2009

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

64. Fetzima patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481598 ALLERGAN Stable dosage forms of levomilnacipran
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage

FETZIMA family patents

Family Patents

65. Gelnique patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8920392 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Mar, 2031

(7 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage

GELNIQUE family patents

Family Patents

66. Giapreza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 2021-12-21

Market Authorisation Date: 21 December, 2017

Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage

GIAPREZA family patents

Family Patents

67. Giazo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497256 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
Jun, 2031

(7 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 03 February, 2012

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET;ORAL

How can I launch a generic of GIAZO before it's drug patent expiration?
More Information on Dosage

GIAZO family patents

Family Patents

68. Gilotrif patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 12, 2025
M (M) Apr 7, 2025
Pediatric Exclusivity (PED) Oct 7, 2025

Drugs and Companies using AFATINIB DIMALEATE ingredient

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents

69. Harvoni patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 7, 2024
ODE* (ODE*) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

HARVONI family patents

Family Patents

70. Hysingla Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(7 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's drug patent expiration?
More Information on Dosage

HYSINGLA ER family patents

Family Patents

71. Imbruvica patents expiration

IMBRUVICA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9125889 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10478439 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US8999999 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9801881 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US10004746 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9814721 PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US10016435 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US8754090 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US9801883 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10653696 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(7 years from now)

US10751342 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

US10478439

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9801883

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US8999999

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US8754090

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9814721

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US10751342

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9125889

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US9801881

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US10016435

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

US10653696

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(7 years from now)

US10004746

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2029
New Patient Population (NPP) Aug 24, 2025
ODE* (ODE*) Aug 2, 2024
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 13 November, 2013

Treatment: Treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of small lymphocytic lymphoma; Treatment of chronic graft versus host disease after...

Dosage: CAPSULE;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

72. Imbruvica patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11672803 PHARMACYCLICS LLC Use of inhibitors of Brutons tyrosine kinase (Btk)
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2029
New Patient Population (NPP) Aug 24, 2025
ODE* (ODE*) Aug 2, 2024
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 13 November, 2013

Treatment: Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia with 17p deleti...

Dosage: CAPSULE;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

73. Ingrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 18, 2030
New Indication (I) Aug 18, 2026

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Market Authorisation Date: 11 April, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage

INGREZZA family patents

Family Patents

74. Inomax patents expiration

INOMAX Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8776795 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US9408993 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(6 years from now)

US9265911 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US9295802 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US8291904 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US8776794 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(6 years from now)

US8573210 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(6 years from now)

US8573209 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US9295802

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US9408993

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(7 years from now)

US9265911

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US8573209

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US8573210

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(7 years from now)

US8291904

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US8776795

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US8776794

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(7 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing a predetermined concentration of nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery...

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage

INOMAX family patents

Family Patents

75. Inrebic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7528143 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Nov, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 16, 2026
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

INREBIC family patents

Family Patents

76. Intrarosa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268806 MILLICENT Pharmaceutical compositions
Mar, 2031

(7 years from now)

Drugs and Companies using PRASTERONE ingredient

Market Authorisation Date: 16 November, 2016

Treatment: NA

Dosage: INSERT;VAGINAL

More Information on Dosage

INTRAROSA family patents

Family Patents

77. Invega Sustenna patents expiration

INVEGA SUSTENNA's oppositions filed in EPO
INVEGA SUSTENNA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters
Jan, 2031

(6 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorde...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA SUSTENNA before it's drug patent expiration?
More Information on Dosage

INVEGA SUSTENNA family patents

Family Patents

78. Invokana patents expiration

INVOKANA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 ...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage

INVOKANA family patents

Family Patents

79. Ionsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9364656 THE MEDICINES CO Method of storing an electrotransport drug delivery device
Sep, 2031

(7 years from now)

US8301238 THE MEDICINES CO Two-part electrotransport device
Sep, 2031

(7 years from now)

US9731121 THE MEDICINES CO Switch validation circuit and method
Oct, 2031

(7 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

IONSYS family patents

Family Patents

80. Isentress patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311

(Pediatric)

MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Apr, 2031

(7 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents

81. Isturisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 2024-03-06

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

Family Patents

82. Jelmyto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9950069 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(6 years from now)

US9040074 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 15, 2027

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 15 April, 2020

Treatment: NA

Dosage: POWDER;PYELOCALYCEAL

More Information on Dosage

JELMYTO family patents

Family Patents

83. Jevtana Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

Market Authorisation Date: 17 June, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage

JEVTANA KIT family patents

Family Patents

84. Juluca patents expiration

JULUCA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.